Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-T1D-1 tirzepatide in adults with type 1 diabetes and overweight or obesity
MOH_2025-05-06_014052Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tirzepatide in diabetes mellitus type 1 (T1D), obesity and Overweight (5 arms), sponsored by Eli Lilly and Company. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
03
Conditions
diabetes mellitus type 1 (T1D)obesityOverweight
Beyond the preview
Go deeper on MOH_2025-05-06_014052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-05-06_014052.